AADvac 1

Drug Profile

AADvac 1

Alternative Names: AADvac-1; Alzheimer's disease vaccine - Axon Neuroscience; Axon peptide 108 conjugated to KLH; Axon peptide 108 coupled to KLH

Latest Information Update: 15 Dec 2016

Price : $50

At a glance

  • Originator Axon Neuroscience
  • Class Alzheimer vaccines
  • Mechanism of Action Immunostimulants; Tau protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Alzheimer's disease

Most Recent Events

  • 29 Apr 2016 Biomarkers information updated
  • 01 Mar 2016 Phase-II clinical trials in Alzheimer's disease in Slovakia and Austria (SC) (NCT02579252)
  • 11 Nov 2015 Adverse events data from a phase I trial in Alzheimer's disease released by Axon Neuroscience
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top